Breast Cancer News
In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
(Reuters) - AstraZeneca Plc is selling breast cancer drug Arimidex directly to U.S. patients, offering an option for people who want to pay for the brand instead of generic versions.
WASHINGTON (Reuters) - Reviewers from the U.S. Food and Drug Administration said on Monday that they were not sure whether Amgen Inc's Xgeva bone drug should be approved for a wider use of delaying the spread of cancer to the bone.
Learn how the combination of everolimus and the hormonal therapy exemestane may offer a new treatment option for postmenopausal women with locally advanced or metastatic estrogen-receptor positive, HER2-negative breast cancer.
Learn how the experiemental medicine pertuzumab improves progression-free survival and may offer a new treatment option for women with metastatic HER2 positive breast cancer.
WASHINGTON (Reuters) - U.S. drug regulators on Friday withdrew approval of Roche's Avastin as a treatment for breast cancer, capping a protracted and emotional battle over a drug backed by many survivors of the disease.
NEW YORK (Reuters Health) - An international survey of cancer doctors shows many question U.S. health advisers' 2010 rejection of Roche's drug Avastin to treat advanced breast cancer.
(Reuters) - Health insurer Blue Shield of California has decided not to pay for Roche Holding's drug Avastin to treat breast cancer after health advisers said it was not safe or clinically beneficial.
STOCKHOLM (Reuters) - Combining two drugs from Novartis and Pfizer to treat post-menopausal women with a certain type of advanced breast cancer more than doubled the time they lived without their disease getting worse, study data showed on Monday.
ZURICH (Reuters) - Patients with advanced breast cancer lived significantly longer without their disease getting worse when treated with Roche's pertuzumab and Herceptin along with a type of chemotherapy, a late-stage study showed.
ZURICH (Reuters) - Novartis AG said a late-stage study showed its drug hope Afinitor slowed tumor growth in advanced breast cancer, helping its chances of becoming a new blockbuster treatment.